Summary

Eligibility
for people ages 18-65 (full criteria)
Location
at San Francisco, California
Dates
study started
completion around
Principal Investigator
by Joshua Woolley, MD, PhDJoaquin Anguera, PhD
Headshot of Joshua Woolley
Joshua Woolley

Description

Summary

The investigators will complete an entirely remote randomized controlled trial (RCT) comparing 14 sessions of attention bias modification (ABM), attention control training (ACT), placebo neutral attention training, and a final control condition with daily questions in 1,897 individuals with clinically significant Post-traumatic Stress Symptoms (PTSS) (defined as PCL-5 score ≥ 33). To assess effects of the training and control conditions, the investigators will administer tests of threat-related attention bias and variability, and self-report assessments of PTSS, depression, anxiety, and perceived stress at baseline, after one and two weeks of training, and at eight-week follow up. The investigators plan to screen and confirm interest from over 3,000 eligible participants over a period of 24 months to enroll and randomize 1,897 participants with the end goal of 1,232 completers (176 per condition).

Official Title

Optimizing Attention Bias Modification for Posttraumatic Stress Disorder: An Entirely Remote Study

Keywords

Post Traumatic Stress Disorder, Attention bias, Traumatic Stress Disorders, Post-Traumatic Stress Disorders, SMART Mobile App - Attention Bias Modification, Attention Bias Modification - Word Stimuli, Attention Bias Modification - Face Stimuli

Eligibility

Location

  • Tommy Atwater accepting new patients
    San Francisco California 94143 United States

Lead Scientists at UCSF

  • Joshua Woolley, MD, PhD
    Dr. Josh Woolley is an Associate Professor in Residence in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco (UCSF) as well as a staff psychiatrist in Mental Health at the San Francisco Veterans Affairs Medical Center (SFVAMC). He is Board Certified in Psychiatry by the American Board of Psychiatry and Neurology.
  • Joaquin Anguera, PhD

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT04888169
Study Type
Interventional
Participants
Expecting 1897 study participants
Last Updated